

Date: 13 February 2025

To
**The Corporate Relationship Department,
BSE Limited**
P.J Towers, 1st Floor,
Dalal Street,
Mumbai – 400001, MH

**Subject: Outcome of the Board Meeting of the Company pursuant to Regulation 30 of
the SEBI (Listing Obligations and Disclosures) Requirements, 2015**
Ref: BSE Script Code: 530617

Sir / Madam,

In reference to our letter dated 8 February 2025, we wish to inform you that the Board of Directors at their meeting held today i.e., 13 February 2025, have inter-alia, approved the following:

1. Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine-month period ended 31 December 2024

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine-month period ended 31 December 2024, accompanied by Limited Review Report issued by the Statutory Auditors of the Company.

2. Appointment of Vinay Kumar Verma as an Additional Director (Non-Executive Independent Director) for a period of 5 (Five) Years

We hereby inform you that the Board of Directors of the Company at its meeting held on 13 February 2025, on the recommendation of the Nomination and Remuneration Committee, has considered and approved the appointment of Vinay Kumar Verma (DIN: 07603237) as an Additional (Non-Executive – Independent) Director for a period of 5 (Five) years with effect from 13 February 2025. The aforesaid appointment is subject to approval of Shareholders in terms of Regulation 17(1C) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A Brief profile of Vinay Kumar Verma in terms of SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13 July 2023 and other details are enclosed herewith as Annexure – A. Further, in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015 it is declared that Vinay Kumar Verma do not hold any shares in

the Company and he is not debarred from holding the office of the Director by virtue of any order of the Securities and Exchange Board of India or any other regulatory authority.

3. Proposal to issue specified securities on Preferential Basis

The Board of Directors discussed the matter and deferred the matter for future Board Meeting.

4. Approval of Extra-Ordinary General Meeting / Postal Ballot for shareholders

The Board of Directors discussed the matter and deferred the matter for future Board Meeting.

The Board Meeting Commenced at 5:00 P.M. IST and concluded on 6:30 P.M. IST.

This is for your information and records.

Sincerely,

For Sampre Nutritions Limited

Brahma Gurbani
(DIN: 00318180)
Managing Director

Annexure A

Details required under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023

Details of Vinay Kumar Verma:

Sl. No.	Particulars	Remarks
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment as Additional (Non-Executive – Independent) Director
2.	Date of Appointment	13 February 2025
3.	Brief Profile (In Case of Appointment)	Vinay Kumar Verma has 40 years of banking experience, having held leadership roles in Andhra Bank, including General Manager and Zonal Manager. He served as CEO and Secretary of Vardhaman (Mahila) Cooperative Urban Bank and was an Independent Director at Nabsamrudhhi Finance Ltd. His expertise spans strategic planning, corporate finance, priority sector lending, and government business. He holds an MBA from NMIMS, Mumbai, and certifications in corporate governance and banking.
4.	Disclosure of Relationships between Directors (in case of appointment of Director)	Vinay Kumar Verma is not related to any Director(s) or Key Managerial Personnel.

SAMPRE NUTRITIONS LIMITED



SAMPRE NUTRITIONS LIMITED
Registered Office: Plot No.133, Industrial Estate, Medchal – 501 401.
Website: www.samprepltd.com; Email: gurbani@gurbanigroup.in

STATEMENT OF STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31st DECEMBER, 2024
CIN: L15499TG1991PLC013515

(Rs. In Lakhs)

S.No.	Particulars	Quarter ended on			Nine Months ended on		Year ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	Income from Operations						
	(a) Revenue from operations	557.80	726.88	699.25	1735.89	2038.28	2514.68
	(b) Other Income	4.38	0.00	0.29	6.91	3.03	11.81
	Total Revenue (1)	562.18	726.88	699.54	1,742.80	2,041.31	2,526.49
2	Expenses:						
	(a) Cost of Materials Consumed	130.42	173.30	261.78	349.67	902.87	953.40
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Change in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employees benefits expense	253.22	268.27	244.47	675.75	650.85	775.15
	(e) Finance costs	58.57	44.63	46.94	148.60	144.13	192.06
	(f) Depreciation and amortisation expenses	43.52	43.52	30.57	130.56	91.64	183.29
	(g) Manufacturing expenses						
	(h) Research & Development expenses						
	(i) Other Expenditure	130.17	184.71	95.89	454.85	275.80	366.06
	Total Expenses (2)	615.90	714.43	679.65	1,759.43	2,065.29	2,469.96
3	Profit/Loss before exceptional and extraordinary items and tax (1-2)	-53.72	12.45	19.89	-16.63	-23.98	56.53
4	Exceptional Items						
5	Profit/Loss before extraordinary items and tax (3-4)	-53.72	12.45	19.89	-16.63	-23.98	56.53
6	Tax Expenses:						
	(1). Current tax						
	(2). Deferred tax						
7	Profit/Loss for the period from continuing operations (5-6)	-53.72	12.45	19.89	-16.63	-23.98	56.53
8	Profit/Loss from discontinued operations						
9	Tax expenses of discontinued operations						
10	Profit/Loss from discontinued operations after tax (8-9)						
11	Profit/Loss for the period (7+10)	-53.72	12.45	19.89	-16.63	-23.98	56.53
12	Other Comprehensive Income						
	A (1). Items that will not be reclassified to profit or loss						
	(2). Incometax relating to items that will not be reclassified to profit or loss						
	B (1). Items that will be reclassified to profit or loss						
	(2). Incometax relating to items that will be reclassified to profit or loss						
	Total Comprehensive Income for the period (11+12)						
13	(comprising Profit/Loss) and other comprehensive income for the period	-53.72	12.45	19.89	-16.63	-23.98	56.53
14	Paid Up Equity Capital (Face value of Rs.10/- each Number)	179.61	72.70	68.70	179.61	68.70	68.70
15	Reserves excluding Revaluation Reserves as per balance sheet of Previous accounting year						
16	Earning Per Equity Share (EPS) for continuing operations						
	A) Basic	(0.30)	0.14	0.29	(0.09)	(0.35)	0.43
	B) Diluted	(0.29)	0.14	0.21	(0.09)	(0.25)	0.33

Notes:

- The above results were approved by the Board of Directors of the Company at its meeting held on 13th February, 2025 and the statutory auditors of the company have carried out limited review of the same.
- The Company is having Subsidiary, Joint Venture and Associate, hence consolidated results are published.
- The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS) on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided. During the year the Company has issued 100 Bonds (FCCB) at 15% Discount and received amount against Foreign Currency Convertible Bonds (FCCB) of 100 Bonds for USD 10.00 Million (Ten Millions United states Dollars). During the Quarter Out of 100 Bonds 64 Bonds were converted fully against Equity shares of 89,91,711 shares. Other bonds are yet to be converted.
- There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor complaints during the quarter.
- Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Place : Hyderabad
Date : 13.02.2025



For and on behalf of the Board
Sampre Nutritions Limited

Managing Director
Brahma Gurbani
DIN : 00318180

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS**TO THE BOARD OF DIRECTORS OF
SAMPRE NUTRITIONS LIMITED**

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SAMPRE NUTRITIONS LIMITED** ("the Company"), for the quarter and nine months ended December 31st 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G Rao & Associates
Chartered Accountants
Firm Registration Number: 009399S**CA. G. Nageswara Rao**
Partner
Membership No. 207300
UDIN: 25207300BMIJUV4036**Place: Hyderabad**
Date: 13-02-2025

SAMPRE NUTRITIONS LIMITED



SAMPRE NUTRITIONS LIMITED
 Registered Office: Plot No.133, Industrial Estate, Medchal – 501 401.
 Website: www.sampre ltd.com; Email: gurbani@gurbanigroup.in
CONSOLIDATED STATEMENT OF UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31st DECEMBER, 2024
 CIN: L15499TG1991PLC013515

		Quarter ended on			Nine Months ended on		Year ended
S.No.	Particulars	31.12.2024 (un audited)	30.09.2024 (un audited)	31.12.2023 (Audited)	31.12.2024 (un audited)	31.12.2023 (Audited)	31.03.2024 (Audited)
1	Income from Operations						
	(a) Revenue from operations	557.80	726.88	-	1735.89	-	2514.68
	(b) Other Income	4.38	0.00	-	6.91	-	11.81
	Total Revenue (1)	562.18	726.88	-	1742.80	-	2526.49
2	Expenses:						
	(a) Cost of Materials Consumed	130.42	173.30	-	349.67	-	953.39
	(b) Purchase of stock-in-trade	0.00	0.00	-	0.00	-	0.00
	(c) Change in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	-	0.00	-	0.00
	(d) Employees benefits expense	253.22	268.27	-	675.75	-	775.15
	(e) Finance costs	58.57	44.63	-	148.60	-	192.24
	(f) Depreciation and amortisation expenses	43.52	43.52	-	130.56	-	183.29
	(g) Manufacturing expenses						
	(h) Research & Development expenses						
	(i) Other Expenditure	130.64	184.71	-	470.07	-	373.66
	Total Expenses (2)	616.37	714.43	-	1774.65	-	2,477.73
3	Profit/Loss before exceptional and extraordinary items and tax (1-2)	-54.19	12.45	-	-31.85	-	48.76
4	Exceptional Items						
5	Profit/Loss before extraordinary items and tax (3-4)	-54.19	12.45	-	-31.85	-	48.76
6	Tax Expenses:						
	(1). Current tax						
	(2). Deferred tax						25.58
7	Profit/Loss for the period from continuing operations (5-6)	(54.19)	12.45	-	-31.85	-	23.18
8	Profit/Loss from discontinued operations						
9	Tax expenses of discontinued operations						
10	Profit/Loss from discontinued operations after tax (8-9)						
11	Profit/Loss for the period (7+10)	-54.19	12.45	-	-31.85	-	23.18
12	Other Comprehensive Income						
	A (1). Items that will not be reclassified to profit or loss						
	(2). Incometax relating to items that will not be reclassified to profit or loss						
	B (1). Items that will be reclassified to profit or loss						
	(2). Incometax relating to items that will be reclassified to profit or loss						
	Total Comprehensive Income for the period (11+12)						
13	(comprising Profit/Loss) and other comprehensive income for the period	-54.19	12.45	-	-31.85	-	23.18
14	Paid Up Equity Capital (Face value of Rs.10/- each)	179.61	72.70	-	179.61	-	68.70
15	Reserves excluding Revaluation Reserves as per balance sheet of Previous accounting year						
16	Earning Per Equity Share (EPS) for continuing operations						
	A) Basic	(0.30)	0.14	-	(0.18)	-	0.32
	B) Diluted						
17	Earning Per Equity Share (EPS) for discontinuing operations						
	A) Basic						
	B) Diluted						
18	Earning Per Equity Share (EPS) for discontinuing & continuing operations						
	A) Basic	(0.30)	0.14	-	(0.18)	-	0.32
	B) Diluted	(0.29)	0.14	-	(0.17)	-	0.24

Notes:

- The above results were approved by the Board of Directors of the Company at its meeting held on 13th February, 2025 and the statutory auditors of the company have carried out limited review of the same.
- The Company is having Subsidiary, called **Sampre Nutritions FZCO, UAE**, hence consolidated results are published.
- The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS) on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided.
- During the year the Company has issued 100 Bonds (FCCB) at 15% Discount and received amount against Foreign Currency Convertible Bonds (FCCB) of 100 Bonds for USD 10.00 Million (Ten Millions United states Dollars). During the Quarter Out of 100 Bonds 64 Bonds were converted fully against Equity shares of 89,91,711 shares. Other bonds are yet to be converted.
- There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor complaints during the quarter.
- Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Place : Hyderabad
 Date : 13.02.2025



For and on behalf of the Board
 Sampre Nutritions Limited

(Signature)
 Managing Director
 Brahma Gurbani
 DIN : 00318180

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
M/s. SAMPRE NUTRITIONS LIMITED

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s. SAMPRE NUTRITIONS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended 31st December, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the following entities:

S.No.	Name of the Entity
1	M/S Sampre Nutritions FZCO (Subsidiary)

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



We did not review the interim financial information of subsidiary company which are included in the consolidated quarterly and nine months ended unaudited financial results, whose interim financial results include total revenue Rs.0.00 Lakhs and Rs.0.00 for the respective quarter and nine months ended 31st December 2024, in respect of 1 subsidiary, which have been reviewed by other auditors, which financial statements, other financial information and auditor's reports have been furnished to us by the management. Our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries is based solely on the reports of such other auditors.

For N G Rao & Associates
Chartered Accountants
Firm Registration Number: 009399S



CA. G. Nageswara Rao
Partner
Membership No. 207300
UDIN: 25207300BMIJUW9155

Place: Hyderabad
Date: 13-02-2025